A Rare Case of Metastatic Spiradenocarcinoma With CDKN2A Mutation

Oncology (Williston Park). 2024 Jun 10;38(6):230-231. doi: 10.46883/2024.25921022.

Abstract

Spiradenocarcinomas are rare malignant skin adnexal tumors. We describe a novel case of a patient with an aggressive CDKN2A-mutated spiradenocarcinoma who responded to a CDK4/6 inhibitor. This case highlights the unique nature of spiradenocarcinomas as well as the potential benefit of targeted therapy.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology
  • Cyclin-Dependent Kinase 4 / genetics
  • Cyclin-Dependent Kinase 6 / antagonists & inhibitors
  • Cyclin-Dependent Kinase 6 / genetics
  • Cyclin-Dependent Kinase Inhibitor p16* / genetics
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mutation*
  • Piperazines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridines / therapeutic use
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / genetics
  • Skin Neoplasms / pathology
  • Sweat Gland Neoplasms / drug therapy
  • Sweat Gland Neoplasms / genetics
  • Sweat Gland Neoplasms / pathology

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • CDKN2A protein, human
  • Cyclin-Dependent Kinase 4
  • Protein Kinase Inhibitors
  • Cyclin-Dependent Kinase 6
  • palbociclib
  • Pyridines
  • Piperazines